1. Rolls-Royce surges to new record high
Expectations were high, but the engineering giant still beat them and raised its full-year guidance.
2. Shell edges higher as cost savings impress
The oil giant delivered second-quarter results that topped expectations, with investors giving a guarded welcome to another robust update.
3. FTSE 100 surges to new record high but ends lower
The London benchmark ended up four points lower at 9,132.8, after topping 9,190 earlier.
4. Just Group agrees takeover offer at 75% premium
The FTSE 250 retirement group soared after Brookfield Wealth Solutions announced a £2.4 billion recommended cash offer, the tenth takeover bid over £1 billion for London-listed companies so far this year.
5. AI at the heart: IXICO’s technology roadmap for the future
CEO Bram Goorden discusses how artificial intelligence powers IXICO’s platform, enabling faster, more accurate neuro image analysis.
More small cap news
- Endeavour Mining PLC (LSE:EDV, TSX:EDV, OTCQX:EDVMF) produced 647,000 ounces of gold in H1 and posted record free cash flow of $514 million. Shareholders get a $150 million dividend, while the company stays on track to hit full-year production and cost targets.
- Gemfields Group Limited (AIM:GEM) pulled in $60 million at auction in the first half and restarted mining at Kagem in May. Its second ruby plant in Mozambique is nearly complete, with production expected in August.
- Atlantic Lithium Ltd (AIM:ALL, OTCQX:ALLIF, ASX:A11) is waiting on parliamentary approval for its Ewoyaa lease in Ghana, while cutting costs to weather low lithium prices. Meanwhile, the explorer says lithium finds in Côte d’Ivoire offer upside potential at a low cost.
- London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) now has over 1,000 Bitcoin miners running across North America, producing 100 petahash per second. The company says the milestone strengthens its balance sheet and aligns with Bitcoin’s long-term economics.
- Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) reported strong results for its six-dose allergy jab, Grass MATA MPL. Three new studies show the treatment cuts symptoms by over 20%, with a potential German launch next year.